Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (October 2025)
30 slides from Nasus Pharma's investor presentation, October 2025
Slide 1: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation of Nasus Pharma Ltd. contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions
Slide 3: Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery
Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery Proprietary Nasax powder Initial focus on medical NS002 intranasal Epinephrine Successful Phase 3 of technology aims to enhance emergencies in Phase 2* demonstrated intranasal Naloxone (NS001) intranasal drug ab
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Medical Emergencies Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Additional Phase 2 NS002 Epinephrine Anaphylaxis Phase 2 completed March 2023 study planned for Q4/20
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Absorption ar
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 8: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Expensive autoinjectors1 with a 12-18 month shelf-life Product candidate aims to offer Epinephrine autoinjectors are a needle-free, convenient, expensive (>$600 before the easily administered, longer
Slide 9: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among the global population1 ~$2.3B Global Epinephrine market in 20242 ~40M Patients with type 1 allergies in the U.S.3 +6.5% From 2010 to 20233 CAGR Patients experience severe type I ~20M allergic reactio
Slide 10: NS002: Completed Milestones
NS002: Completed Milestones Completed Completed NS002 NS002/EpiPen pilot study Comparative Phase 2 study Q3 2021 Q2 2022 Q1 2023 Pre-IND meeting w/ FDA 10
Slide 11: NS002: Pilot Study Overview
NS002: Pilot Study Overview 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Period 2 2-3 weeks washout Day 1 Day 2 Day 3 Day 1 Day 2 Single IM injection Nasus Product in Nasal allergen Nasus Product 1.6mg Nasal allergen of EpiPen one nos
Slide 12: Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen
Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. 12
Slide 13: NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen
NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Nasus 1.6mg+A
Slide 14: NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen
NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen Pilot study pharmacodynamics (PD) Systolic Blood Pressure 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challenge 100 0 0
Slide 15: NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose
NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose for Phase 3 1 week 1 week Arm 1: N=6 B C A Nasus spray 3.6mg Nasus spray 4.0mg On each dosing day: EpiPen in one nostril in one nostril Screening PK sampling: 12 healthy -1 to 2hr. (13 samples) v
Slide 16: Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold at 6 Minutes
Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold of Epinephrine by NS002 Compared to EpiPen at 6 Minutes Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects 6min EpiPen 55 % Nasus 3.6mg 72 % Nasus 4.0mg 91% Proportion of subjects achieving clinical threshold of 1
Slide 17: Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen
Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen Mean AUC0-4min +SD Mean AUC0-10min +SD 70 140 60 120 Mean AUC h*pg/mL Mean AUC h*pg/mL 50 100 40 80 27.44 63.96 30 50.99 60 20 14.17 40 27.38 10 5.85 20 0 Phase 2 EpiPen Nasus 3.6mg Nasus 4.0mg 0 EpiPen Nasus 3.6mg Nas
Slide 18: Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine
Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen – Including Time to Hemodynamic Therapeutic Threshold 100pg/ml Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) T100pg/mL (median, minutes) Cmax (Geometric mean + SD) 1400 16
Slide 19: Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen
Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen Heart Rate Heart Rate Systolic Blood Pressure 140 90 130 85 Systolic BP (mean) Phase 2: 80 HR (mean) 120 PD results 110 75 70 100 65 90 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Respiration Rate Dia
Slide 20: NS002: Phase 2 Results Summary
NS002: Phase 2 Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors 01 NS002 reached the hemodynamic therapeutic plasma threshold faster than epipen 02 Nasax powder was well tolerated with transient mild symptoms 03 Maximum epinephrine absorption (tmax) achieved signi
Slide 21: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine ARS Pharma1 Aquestive4 Nasus Pharma5 PK Parameters Bryn Pharma2 Orexo3 EpiPen5 (Market Cap ~$1B) (Market Cap ~$700M) (Market Cap ~$70M) Cmax (Mean) (pg/ml) 341 429 377 497 360 477 Tmax (Median) 30 20 25
Slide 22: NS002: Clear Roadmap to Commercialization
NS002: Clear Roadmap to Commercialization • Following FDA guidance based on the 505b2 regulatory pathway • Demonstration of comparable PK/PD to EpiPen only requirement for regulatory approval • Short and cost-effective clinical studies • Proven experience gained through the development of intranasal
Slide 23: NS002: Upcoming Phase 2 Study, Designed to Compare Bioavailability and PK of Repeat Dosing
NS002: Upcoming Phase 2 Study, Designed to Compare Bioavailability and PK of Repeat Dosing Topline results of the first pre-planned interim analysis expected in Q1 2026 Week 7: Week 5: Nasal allergic 2xNS002 4mg challenge R+L nostrils 2xNS002 4mg R+L nostrils Week 1: Screening Week 4: Nasal allergic
Slide 24: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE 24
Slide 25: Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan The res
Slide 26: Simplified Supply Chain
Simplified Supply Chain Unidose (UDS) Powder Nasal Spray System (Aptar) Fill, finish, package API Nasal powder (NS002 – epinepherine) manufacture (NS001 – naloxone) 26
Slide 27: Nasus is Uniquely Positioned to Address Medical Emergencies
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead asset NS002 is a needle-free, convenient, easily administered alternative to Epinephrine autoinjector, directly addressing the current unmet need Nasus is Uniquely Positive Phase 2 data demonstrated NS002 deliver
Slide 28: Robust Patent Portfolio
Robust Patent Portfolio Country Filed Patent No./ Publication No. Grant Date/ Pub. Date Status Expiration Date(2) USA 8/20/2017 Term Ended PCT(1) 8/19/2018 WO 2019/038756 A1 National Phase entered 8/19/2038 Australia 8/19/2018 Grant Fee Paid 8/19/2038 Canada 8/19/2018 Office Action due: 10/22/2024 8
Slide 29: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and Carolina Abrutzky, VP of CMC pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN)
Slide 30: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame